Kezdőlap・Részvénylista・Cerus Corp

Cerus Corp

Lezárt

SzektorEgészségügy

2.34 1.3

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

2.2

Maximum

2.35

Fő mutatók
By Trading Economics
Bevétel	-1.3M -3M
Értékesítés	-2.5M 57M
Egy részvényre jutó nyereség	-0.01
Profit margin	-5.191
Munkavállalók	261
EBITDA	-1.5M -712K

Ajánlások
By TipRanks
Ajánlások	Vétel
12 hónapos előrejelzés	+120.26% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 5.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-182M 433M
Előző nyitás	1.04
Előző zárás	2.34

Hangulat hírek alapján

By Acuity

50%

156 / 340 Rangsor szerint Healthcare

Cerus Corp Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 5. 19:43 UTC

Cerus Corp shares are higher Wednesday, recovering from an earlier decline amid high trading volume. Broader market sentiment is influenced by ADP's employment report.

2026. aug. 4. 19:11 UTC

Correlated Moves

Cerus Corp shares are higher amid increased trading volume and positive market trends, despite concerns over declining U.S. core factory orders.

2026. aug. 3. 19:56 UTC

Correlated Moves

Cerus Corp shares are higher, supported by broader market strength and a rally in the health care supplies sector. The stock remains below its 20-day moving average.

2026. júl. 31. 23:06 UTC

Cerus Corp shares are higher in after-market trading, reflecting a notable increase since Friday's close, despite being below its 20-day moving average.

2026. júl. 30. 23:41 UTC

News

Cerus Corporation shares declined in after-market hours following a revenue miss and lowered full-year guidance, despite second-quarter earnings matching estimates.

2026. júl. 29. 19:56 UTC

Macro Event

Cerus Corp shares are lower as macroeconomic factors, including steady interest rates and rising oil prices, create market volatility. The stock is near its one-month low.

2026. júl. 28. 16:02 UTC

Cerus Corp shares are lower today, reflecting broader market pressures amid a risk-off sentiment following declines in tech-heavy indices like Japan's Nikkei 225.

2026. júl. 27. 20:07 UTC

Cerus Corp shares are higher in Monday's session, reaching a peak of 6.12%. Broader market factors include declining oil prices and lower Treasury yields.

2026. júl. 24. 19:06 UTC

Cerus Corp shares are higher, supported by a decline in crude oil prices that eased inflationary pressures. The stock remains below its 20-day moving average.

2026. júl. 23. 09:01 UTC

Cerus Corp shares are lower in pre-market hours, continuing a downward trend. The stock remains significantly below its 20-day moving average.

2026. júl. 22. 15:46 UTC

Cerus Corp. shares are trading roughly flat, with no specific news identified. The stock remains above its 20-day moving average after a month of gains.

2026. júl. 21. 21:41 UTC

Cerus Corp shares are lower in after-market hours, declining steadily after an early peak. No specific news was identified to explain the movement.

Társak összehasonlítása

Árváltozás

Cerus Corp Előrejelzés

Célár

By TipRanks

120.26% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 5 USD 120.26%

Magas 5 USD

Alacsony 5 USD

1 Wall Street elemző 12 hónapos célárain alapulva a(z)Cerus Corp termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

1 ratings

Vétel

Tartás

Eladás

1 Wall Street elemző célárain alapulva a(z)Cerus Corp termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

156 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.